Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of NT 201 in pediatric spasticity
jRCT2051240254Active, not recruiting
- Sponsor
- Teijin Pharma
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in upper extremity spasticity and lower extremity spasticity, sponsored by Teijin Pharma. Primary endpoints: Change in MAS score of wrist flexors at 4 weeks and Change in MAS score of plantar flexors at 4 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
upper extremity spasticitylower extremity spasticity
Beyond the preview
Go deeper on jRCT2051240254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240254.